TV News LIES

Monday, Dec 22nd

Last update02:32:49 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


Hope for dementia patients: Study suggests lost memories can be restored

Memory loss might be restorableResearchers at UCLA say new science suggests lost memories are restorable, lending hope to the millions...

NY releases planned medical marijuana rules

NY medical marijuanaThe state took another step Thursday toward getting its medical marijuana program up and running, with...

Health study: Half of Dr. Oz's advice is bad

Dr. Oz information flawedThe British Medical Journal examined popular daytime medical talk shows "The Doctors" and "The Dr. Oz...

Ebola kills Sierra Leone's most senior doctor

Ebola kills senior doctorSierra Leone’s most senior doctor has died of Ebola just hours after an experimental drug to...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!